Announced that positive preclinical data of selective HDAC6 inhibitor.


We intend to initiate a single agent research with ricolinostat in patients with non-Hodgkin's lymphoma and Hodgkin's lymphoma in 2014, even though we continue to explore optimal combination regimens for ricolinostat in these diseases. Related StoriesPresident and CEO of Proteins Sciences elected as 2015 Fellow of the International Society for VaccinesGriffith University uncovers initial 3-D image of protein associated with cancer spreadMyriad RBM's DiscoveryMAP system identifies protein biomarkers associated with CV occasions in diabetes patients Highlights of the Presentations at ASH Dual Targeting With the Selective Histone Deacetylase 6 Inhibitor, ACY-1215, and Bortezomib Qualified prospects to Marked Disruption of Proteins Degradation Pathways and Apoptosis in Preclinical Models of Lymphoma In six lymphoma cell lines, ricolinostat in combination with bortezomib led to a synergistic increase in apoptosis Within an in vivo model of diffuse huge B-cell lymphoma , a single treatment of the combination of ricolinostat and bortezomib demonstrated statistically significant delay in tumor growth and extended general survival Inhibition of HDAC6 in Combination with Targeted Agents Outcomes in Broad Synergistic Decreases in Viability in Non-Hodgkin's Lymphoma Cells Ricolinostat in conjunction with Bruton's tyrosine kinase inhibitor, ibrutinib , or PI3K inhibitors, GDC-0941 and GS-1101, resulted in synergistic decreases in non-Hodgkin's lymphoma cell viability Ricolinostat also demonstrated significant reduction in NHL cell viability as an individual agent..Warren was a graduate pupil in the University of Washington’s Department of Immunology. She was completed by her thesis work with Dr. Alan Aderem at the ISB, where she investigated early signaling occasions that control the magnitude of immune response. This work culminated in significant enhancements to Listeria monocytogenes-structured vaccines that will have implications for vaccines against cancers and infectious disease. Additionally, Dr. Warren joined the Molecular Medicine Plan at the University of Washington, a certificate system designed to train college students to integrate preliminary research with clinical encounters in human disease. Dr. Warren’s scientific teaching began at Iowa State University, where as a National Merit Scholar she double majored in biochemistry and English.